Dr. Reddy's In Bearish Mode Launches Products In U.S. Markets


Stocks of pharma player, Dr. Reddy's are trading weak on BSE, as markets are moving out of early hours of trade, trading down by 0.35% at Rs 2601.80 per share. The pharma player announced today that it has launched Ezetimibe and Simvastatin tablets 10mg/10mg, 10mg/20mg, 10mg/40mg, 10mg/80 mg, a therapeutic equivalent generic version of Vyotrin tablets in U.S. market, being approved by USFDA.

The Vyotrin brand had U.S. sales of nearly $678 million MAT for the most recent 12 months ended in February 2017, as per IMS Health.

The company is among the first to launch generic products in the U.S. market. On a yearly basis, the stock has underperformed BSE Sensex and BSE Healthcare index. The total traded quantity of shares stands at 0.22 lakh; and the market capitalisation at Rs 43,086.46 crore.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 
Share on Google Plus

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: